HPV Associated Disorders Treatment Market Outlook:
HPV Associated Disorders Treatment Market size was valued at USD 20.6 billion in 2025 and is expected to reach USD 32.92 billion by 2035, registering around 4.8% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of HPV associated disorders treatment is evaluated at USD 21.49 billion.
The HPV associated disorders treatment market is experiencing robust growth, driven by the rising prevalence of HPV-associated disorders, including cervical, anal, and oropharyngeal cancers, globally. Diagnostic advancements such as NGS and molecular testing, along with the development of targeted therapies and vaccines are expanding treatment options. For instance, in June 2020, Merck received the U.S. FDA approval for GARDASIL 9, for the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58. Furthermore, government initiatives promoting HPV vaccination and screening programs, especially in developed regions, are further fueling the HPV associated disorders treatment market growth.
